Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer.

Alongi F; Alongi P

doi:10.1016/S1470-2045(26)00008-2

← 뒤로

Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer.

0/5 보강

The Lancet. Oncology 2026 Vol.27(4) p. 400-402

Alongi F, Alongi P

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Alongi F, Alongi P (2026). Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer.. The Lancet. Oncology, 27(4), 400-402. https://doi.org/10.1016/S1470-2045(26)00008-2

MLA Alongi F, et al.. "Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer.." The Lancet. Oncology, vol. 27, no. 4, 2026, pp. 400-402.

PMID 41926955

DOI 10.1016/S1470-2045(26)00008-2

같은 제1저자의 인용 많은 논문 (1)

ESTRO-ISRS clinical practice recommendations for re-irradiation of spinal metastases with Stereotactic Body Radiotherapy: Delphi consensus supported by a systematic review and meta-analysis.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2026